HK1199209A1 - Vegf/dll4 binding agents and uses thereof vegf/dll4 - Google Patents

Vegf/dll4 binding agents and uses thereof vegf/dll4

Info

Publication number
HK1199209A1
HK1199209A1 HK14112776.9A HK14112776A HK1199209A1 HK 1199209 A1 HK1199209 A1 HK 1199209A1 HK 14112776 A HK14112776 A HK 14112776A HK 1199209 A1 HK1199209 A1 HK 1199209A1
Authority
HK
Hong Kong
Prior art keywords
vegf
dll4
binding agents
dll4 binding
agents
Prior art date
Application number
HK14112776.9A
Other languages
English (en)
Chinese (zh)
Inventor
奧斯丁．
．格尼
阿龍．肯．薩拓
．邦德
Original Assignee
Oncomed Pharmaceuticalsinc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticalsinc filed Critical Oncomed Pharmaceuticalsinc
Publication of HK1199209A1 publication Critical patent/HK1199209A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK14112776.9A 2011-09-23 2014-12-22 Vegf/dll4 binding agents and uses thereof vegf/dll4 HK1199209A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161538454P 2011-09-23 2011-09-23
US201261597409P 2012-02-10 2012-02-10
US201261692978P 2012-08-24 2012-08-24
PCT/US2012/056886 WO2013044215A1 (en) 2011-09-23 2012-09-24 Vegf/dll4 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
HK1199209A1 true HK1199209A1 (en) 2015-06-26

Family

ID=47914946

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112776.9A HK1199209A1 (en) 2011-09-23 2014-12-22 Vegf/dll4 binding agents and uses thereof vegf/dll4

Country Status (33)

Country Link
US (8) US8858941B2 (ja)
EP (2) EP2758073B1 (ja)
JP (1) JP6170496B2 (ja)
KR (1) KR102091293B1 (ja)
CN (2) CN107722122B (ja)
AU (1) AU2013201095C1 (ja)
BR (1) BR112014007035B1 (ja)
CA (1) CA2849562C (ja)
CL (1) CL2014000725A1 (ja)
CO (1) CO6940382A2 (ja)
CR (1) CR20140172A (ja)
CY (1) CY1121148T1 (ja)
DK (2) DK3485903T5 (ja)
EA (1) EA029958B1 (ja)
ES (2) ES2707580T3 (ja)
FI (1) FI3485903T3 (ja)
HK (1) HK1199209A1 (ja)
HR (2) HRP20230078T1 (ja)
HU (2) HUE061002T2 (ja)
IL (1) IL231628B (ja)
IN (1) IN2014KN00871A (ja)
LT (2) LT3485903T (ja)
MX (2) MX361712B (ja)
MY (1) MY188192A (ja)
NI (1) NI201400024A (ja)
PE (1) PE20141537A1 (ja)
PL (2) PL3485903T3 (ja)
PT (2) PT2758073T (ja)
RS (2) RS58201B1 (ja)
SG (1) SG11201400870WA (ja)
SI (2) SI3485903T1 (ja)
TW (1) TWI583699B (ja)
WO (1) WO2013044215A1 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066694B1 (en) 2006-09-29 2015-11-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
JP5964249B2 (ja) 2010-03-02 2016-08-03 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
WO2014071018A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
BR112015009961B1 (pt) * 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
EP3020731B1 (en) * 2013-07-09 2019-06-12 ABLBio Novel dual-targeted protein specifically binding to dll4 and vegf, and use thereof
WO2015130751A1 (en) * 2014-02-26 2015-09-03 Medimmune, Llc Methods of treatment with dll4 antagonists
EP3125937A4 (en) * 2014-04-04 2017-11-01 Oncomed Pharmaceuticals, Inc. Treatment of gastric cancer
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
RS65136B1 (sr) 2014-07-17 2024-02-29 Novo Nordisk As Mutageza usmerena na lokaciju trem-1 antitela za smanjenje viskoziteta
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11339213B2 (en) * 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
JP7253923B2 (ja) * 2016-04-05 2023-04-07 ファイザー・インク 細胞培養プロセス
CN105669871A (zh) * 2016-04-19 2016-06-15 中国药科大学 一种胸腺肽α1的融合蛋白
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
JP2020517591A (ja) 2017-04-24 2020-06-18 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３３抗体剤
CN111132695A (zh) * 2017-08-18 2020-05-08 里珍纳龙药品有限公司 分析样品基质中蛋白变异体的成像毛细管等电聚焦
AU2019248547A1 (en) 2018-04-02 2020-09-10 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
CA3119458A1 (en) 2018-11-15 2020-05-22 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with vegf/dll4 binding agent
AU2020378280A1 (en) 2019-11-07 2022-04-07 Feng Biosciences, Ltd. Classification of tumor microenvironments
CN111234003B (zh) * 2020-02-07 2022-02-01 中国人民解放军第四军医大学 一种用于癌症靶向治疗的短肽及基于其的超声响应纳米载药微泡和应用
EP4314348A1 (en) 2021-03-25 2024-02-07 Oncxerna Therapeutics, Inc. Targeted therapies in cancer
CN114369158B (zh) * 2021-09-28 2024-04-19 北京亦科信息菌素研究院有限公司 一种抗新冠病毒的信息菌素及其应用

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US994637A (en) 1910-09-14 1911-06-06 Dexter Folder Co Paper-cutting machine.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
CA1176659A (en) 1981-09-14 1984-10-23 Gerhard Degischer Process for producing n-substituted-n-acetyl-2,6- dialkylanilines
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5219837A (en) 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE442373T1 (de) 1995-06-28 2009-09-15 Imp Cancer Res Tech Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
JPH09124697A (ja) 1995-11-01 1997-05-13 Toagosei Co Ltd ペプチド及びモノクローナル抗体
JP4283891B2 (ja) 1995-11-17 2009-06-24 旭化成株式会社 分化抑制ポリペプチド
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
EP0972041B2 (en) 1997-04-04 2017-01-18 Millennium Pharmaceuticals, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
US6121045A (en) 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
WO1998051799A1 (fr) 1997-05-14 1998-11-19 Asahi Kasei Kogyo Kabushiki Kaisha Nouvel inhibiteur de differentiation
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
JP2002520007A (ja) 1998-07-13 2002-07-09 イエール ユニバーシティー Ｄｅｌｔａ切断産物およびそれに基づく方法
CA2337492A1 (en) 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
WO2003012441A1 (en) 2001-07-25 2003-02-13 Lorantis Limited Method for detecting modulators of notch signalling
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2003041735A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
US20050137130A1 (en) 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
JP2005511754A (ja) 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
GB0218879D0 (en) 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
JP2006515177A (ja) 2002-09-10 2006-05-25 ロランティス リミテッド Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN1511850A (zh) 2002-12-31 2004-07-14 王小宁 Mhc-肽抗体多聚体的制备方法
JP2006527198A (ja) 2003-06-06 2006-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆインヒビターを用いる腫瘍退縮方法
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
FR2859725B1 (fr) 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
NZ577564A (en) 2003-12-05 2010-04-30 Bioinvent Int Ab Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
WO2005074633A2 (en) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
CN101102786A (zh) 2004-06-10 2008-01-09 瑞泽恩制药公司 施用并利用vegf抑制剂治疗人类癌症的方法
WO2005124364A1 (en) 2004-06-15 2005-12-29 F. Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
EP1615036B1 (en) 2004-07-07 2007-09-19 F.Hoffmann-La Roche Ag Multimarker panel for diabetes type 1 and 2
WO2006024497A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006027693A2 (en) 2004-09-09 2006-03-16 Exonhit Therapeutics Sa Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
AU2005302846A1 (en) 2004-11-10 2006-05-18 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
WO2006077265A1 (en) 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of bnp-type peptides and anp-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
JP2008537538A (ja) 2005-02-11 2008-09-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ拮抗剤及び降圧剤の治療的組み合わせ
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US20070036797A1 (en) 2005-06-02 2007-02-15 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
WO2007022101A2 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
US7774903B2 (en) 2005-08-16 2010-08-17 Lummus Corporation Roller gin apparatus, method and system
WO2007028110A2 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ES2400666T5 (es) 2005-12-16 2016-03-10 Regeneron Pharmaceuticals, Inc. Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
CA2642685A1 (en) 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
WO2007103114A2 (en) 2006-03-07 2007-09-13 The Brigham & Women's Hospital, Inc. Notch inhibition in the treatment or prevention of atherosclerosis
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
TW200817435A (en) 2006-06-06 2008-04-16 Genentech Inc Compositions and methods for modulating vascular development
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
EP2032166B1 (en) 2006-06-13 2013-04-10 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
CA2660235C (en) 2006-08-07 2015-09-22 Regeneron Pharmaceuticals, Inc. Therapeutic methods for treating vascular eye disorders with dll4 antagonists
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2066694B1 (en) 2006-09-29 2015-11-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN101583624B (zh) * 2006-09-29 2012-11-21 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物及其用途
CA2666974A1 (en) 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2008070350A2 (en) 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
US20100166746A1 (en) 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
AU2007333565A1 (en) 2006-12-11 2008-06-19 Genentech, Inc. Compositions and methods for treating a neoplasm
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
SI2101807T1 (sl) 2006-12-19 2016-08-31 Genentech, Inc. VEGF-specifični antagonisti za adjuvansno in neoadjuvansno terapijo in zdravljenje tumorjev v zgodnjem stadiju
WO2008079326A2 (en) 2006-12-20 2008-07-03 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US20100119526A1 (en) 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
MX2009011898A (es) 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
CN101970486A (zh) 2007-10-25 2011-02-09 布里斯托尔大学 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
WO2009075565A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
MX364200B (es) 2008-04-09 2019-04-16 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
JP5560270B2 (ja) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
WO2010010153A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Identification of subjects being susceptible to anti-angiogenesis therapy
EP2324358A1 (en) 2008-07-23 2011-05-25 F. Hoffmann-La Roche AG Monitoring anti-angiogenesis therapy
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
PE20120415A1 (es) 2008-12-12 2012-05-09 Boehringer Ingelheim Int Anticuerpos anti-igf
MX2011010955A (es) 2009-04-20 2012-04-02 Genentech Inc Terapia complementaria contra el cancer.
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US9067986B2 (en) * 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
US9308258B2 (en) 2009-07-08 2016-04-12 Amgen Inc. Stable and aggregation free antibody FC molecules through CH3 domain interface engineering
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
US20120207673A1 (en) 2009-10-23 2012-08-16 Daniel Christ Modified Variable Domain Molecules And Methods For Producing And Using Same
CA2782299A1 (en) * 2009-12-01 2011-06-09 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
MX2012009175A (es) * 2010-02-12 2012-12-17 Oncomed Pharm Inc Metodos para identificar y aislar celulas que expresan un polipeptido.
RU2012140447A (ru) 2010-02-23 2014-03-27 Дженентек, Инк. Антиангиогенная терапия для лечения рака яичника
JP5964249B2 (ja) * 2010-03-02 2016-08-03 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
SG191712A1 (en) 2010-11-02 2013-08-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US20130323265A1 (en) 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
CA2838973A1 (en) 2011-06-17 2012-12-20 Adrian L. Harris Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
WO2013113898A1 (en) 2012-02-03 2013-08-08 Medimmune Limited Process for reducing antibody aggregate levels and antibodies produced thereby
PT2825558T (pt) 2012-03-13 2019-07-11 Hoffmann La Roche Terapêutica combinada para o tratamento do cancro do ovário
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10174107B2 (en) 2012-05-31 2019-01-08 Sorrento Therapeutics, Inc. Antigen binding proteins that bind delta-like 4 (DLL-4)
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
CA2883880A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
US20150368329A1 (en) 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
WO2014071018A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
EP3020731B1 (en) 2013-07-09 2019-06-12 ABLBio Novel dual-targeted protein specifically binding to dll4 and vegf, and use thereof
JP6636920B2 (ja) 2013-07-16 2020-01-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法
WO2015130751A1 (en) 2014-02-26 2015-09-03 Medimmune, Llc Methods of treatment with dll4 antagonists
EP3125937A4 (en) 2014-04-04 2017-11-01 Oncomed Pharmaceuticals, Inc. Treatment of gastric cancer
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
AU2015289621A1 (en) 2014-07-16 2017-01-12 Genentech, Inc. Methods of treating cancer using TIGIT inhibitors and anti-cancer agents
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CN113912724A (zh) 2015-09-25 2022-01-11 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
CA3119458A1 (en) 2018-11-15 2020-05-22 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with vegf/dll4 binding agent

Also Published As

Publication number Publication date
WO2013044215A9 (en) 2014-04-03
JP6170496B2 (ja) 2017-07-26
CN104168914B (zh) 2017-08-08
MY188192A (en) 2021-11-24
BR112014007035B1 (pt) 2021-05-04
BR112014007035A2 (pt) 2017-04-11
AU2013201095A1 (en) 2013-04-11
PE20141537A1 (es) 2014-11-17
CO6940382A2 (es) 2014-05-09
ES2707580T3 (es) 2019-04-04
US8858941B2 (en) 2014-10-14
US10730940B2 (en) 2020-08-04
US20170183406A1 (en) 2017-06-29
HUE042192T2 (hu) 2019-06-28
US20130164295A1 (en) 2013-06-27
US9574009B2 (en) 2017-02-21
PL2758073T3 (pl) 2019-04-30
MX2018010331A (es) 2020-09-02
CN104168914A (zh) 2014-11-26
CA2849562C (en) 2020-07-21
PT3485903T (pt) 2023-02-17
TW201326204A (zh) 2013-07-01
LT2758073T (lt) 2019-01-10
JP2014530599A (ja) 2014-11-20
CA2849562A1 (en) 2013-03-28
CN107722122A (zh) 2018-02-23
US20180305449A1 (en) 2018-10-25
PT2758073T (pt) 2019-02-01
AU2013201095C1 (en) 2019-12-05
HRP20230078T1 (hr) 2023-05-12
NI201400024A (es) 2014-06-26
CL2014000725A1 (es) 2014-09-05
IL231628B (en) 2018-12-31
CN107722122B (zh) 2022-05-27
US20210061903A1 (en) 2021-03-04
DK3485903T3 (da) 2023-02-06
TWI583699B (zh) 2017-05-21
MX361712B (es) 2018-12-14
MX2014003558A (es) 2014-06-23
RS63965B1 (sr) 2023-03-31
US20150098949A1 (en) 2015-04-09
KR20140082719A (ko) 2014-07-02
EA029958B1 (ru) 2018-06-29
HUE061002T2 (hu) 2023-04-28
FI3485903T3 (fi) 2023-01-31
IN2014KN00871A (ja) 2015-08-21
ES2938628T3 (es) 2023-04-13
US11512128B2 (en) 2022-11-29
WO2013044215A1 (en) 2013-03-28
US9376488B2 (en) 2016-06-28
CR20140172A (es) 2014-06-19
KR102091293B1 (ko) 2020-03-20
LT3485903T (lt) 2023-02-27
RS58201B1 (sr) 2019-03-29
EP2758073A1 (en) 2014-07-30
DK3485903T5 (da) 2024-09-02
NZ623724A (en) 2016-09-30
US9879084B2 (en) 2018-01-30
IL231628A0 (en) 2014-05-28
DK2758073T3 (en) 2019-01-14
US20230279101A1 (en) 2023-09-07
SI3485903T1 (sl) 2023-02-28
PL3485903T3 (pl) 2023-06-12
AU2013201095B2 (en) 2015-09-17
EP2758073B1 (en) 2018-10-31
US20160362499A1 (en) 2016-12-15
US20190062424A1 (en) 2019-02-28
SG11201400870WA (en) 2014-04-28
SI2758073T1 (sl) 2019-02-28
EP3485903B1 (en) 2022-11-16
EP3485903A1 (en) 2019-05-22
CY1121148T1 (el) 2020-05-29
EP2758073A4 (en) 2015-04-29
HRP20190044T1 (hr) 2019-02-22
EA201490622A1 (ru) 2014-08-29
WO2013044215A4 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
HRP20190044T1 (hr) Agensi koji vežu vegf/dll4 i njihove uporabe
HUS2400021I1 (hu) Gombaellenes szerek és alkalmazásuk
ZA201400525B (en) Rspo binding agents and uses thereof
HK1208687A1 (en) Rspo3 binding agents and uses thereof rspo3
HK1210964A1 (en) Immunotherapy with binding agents
PT2739695T (pt) Adesivos e respetiva utilização
IL229844B (en) Anti-psgl-1 antibodies and their use
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
EP2693879A4 (en) MIGRASTATINES AND THEIR USES
ZA201402890B (en) Vegf/dll4 binding agents and uses thereof
GB201120454D0 (en) Kit and uses thereof
GB201114341D0 (en) Reagent and use
GB201119443D0 (en) GoWinging Concept and patent